IDEXX Laboratories, Inc. (IDXX)
IDEXX Laboratories Touts AI Push, inVue Dx Momentum at Stifel Conference
IDEXX Laboratories NASDAQ: IDXX President and CEO Michael Erickson used a Stifel investor conference appearance to emphasize the company's innovation pipeline, expanding commercial reach and growing use of software and artificial intelligence across veterinary diagnostics.
IDEXX Laboratories, Inc. (IDXX) Presents at Stifel Jaws & Paws Conference 2026 Transcript
IDEXX Laboratories, Inc. (IDXX) Presents at Stifel Jaws & Paws Conference 2026 Transcript
IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript
IDEXX Laboratories, Inc. (IDXX) Q1 2026 Earnings Call Transcript
Idexx (IDXX) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Idexx Laboratories (IDXX) Q1 Earnings and Revenues Surpass Estimates
Idexx Laboratories (IDXX) came out with quarterly earnings of $3.47 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $2.96 per share a year ago.
Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Idexx Laboratories (IDXX) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Is it a Prudent Move to Retain IDXX Stock in Your Portfolio Now?
IDEXX Laboratories, Inc. IDXX is expanding its global commercial capabilities to support continued growth in its CAG Diagnostics recurring revenue stream. The company's software ecosystem remains a key pillar of its value proposition.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Will Idexx (IDXX) Beat Estimates Again in Its Next Earnings Report?
Idexx (IDXX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
IDEXX Laboratories Stock Up 39.4% in a Year: What's Driving It?
IDXX stock surges over the past year, fueled by strong diagnostics growth, innovation traction and expanding global demand in pet healthcare markets.
Idexx (IDXX) Upgraded to Buy: Here's Why
Idexx (IDXX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
